Second Sight Medical Products (EYES) versus Its Competitors Head to Head Analysis

Second Sight Medical Products (NASDAQ: EYES) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Second Sight Medical Products to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Valuation and Earnings

This table compares Second Sight Medical Products and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Second Sight Medical Products $3.98 million -$33.17 million -2.99
Second Sight Medical Products Competitors $1.67 billion $207.58 million 66.60

Second Sight Medical Products’ rivals have higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Second Sight Medical Products and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Second Sight Medical Products Competitors 113 734 1030 10 2.50

Second Sight Medical Products currently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. As a group, “Medical Devices & Implants” companies have a potential upside of 38.59%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Second Sight Medical Products is more favorable than its rivals.

Profitability

This table compares Second Sight Medical Products and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -565.12% -184.87% -137.77%
Second Sight Medical Products Competitors -101.23% -92.70% -30.32%

Volatility & Risk

Second Sight Medical Products has a beta of 3.67, indicating that its share price is 267% more volatile than the S&P 500. Comparatively, Second Sight Medical Products’ rivals have a beta of 0.21, indicating that their average share price is 79% less volatile than the S&P 500.

Insider & Institutional Ownership

12.7% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 50.9% of Second Sight Medical Products shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Second Sight Medical Products rivals beat Second Sight Medical Products on 8 of the 13 factors compared.

About Second Sight Medical Products

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

What are top analysts saying about Second Sight Medical Products? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Second Sight Medical Products and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit